Therapeutic Opportunities in Colorectal Cancer: Focus on Melatonin Antioncogenic Action
Hucong Wu1,2, Jiaqi Liu1,2, Yi Yin1,2
1College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
Abstract:
Colorectal cancer (CRC) influences individual health worldwide with high morbidity and mortality. Melatonin, which shows multiple physiological functions (e.g., circadian rhythm, immune modulation, and antioncogenic action), can be present in almost all organisms and found in various tissues including gastrointestinal tract. Notably, melatonin disruption is closely associated with the elevation of CRC incidence, indicating that melatonin is effective in suppressing CRC development and progression. Mechanistically, melatonin favors in activating apoptosis and colon cancer immunity, while reducing proliferation, autophagy, metastasis, and angiogenesis, thereby exerting its anticarcinogenic effects. This review highlights that melatonin can be an adjuvant therapy and be beneficial in treating patients suffering from CRC.
Related Concept Videos
Management of Insomnia
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Destabilize Microtubules
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Inhibition of Cdk Activity


